These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1344 related items for PubMed ID: 25756511

  • 1. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C, Wu G, Li R, Gao L, Yang F, Zhao Y, Zhang J, Zhang R, Zhang J, Yao L, Yuan J, Li X.
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [Abstract] [Full Text] [Related]

  • 2. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V, Menon M, Thamilselvan S.
    Int J Cancer; 2016 Oct 01; 139(7):1632-47. PubMed ID: 27198552
    [Abstract] [Full Text] [Related]

  • 3. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A, Larsson K, Welén K, Damber JE.
    Prostate; 2020 Aug 01; 80(11):799-810. PubMed ID: 32449815
    [Abstract] [Full Text] [Related]

  • 4. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.
    Eur Urol; 2018 Jun 01; 73(6):949-960. PubMed ID: 29544736
    [Abstract] [Full Text] [Related]

  • 5. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ, Chen CJ, Lin TY, Liu YY, Tseng LL, Cheng ML, Chuu CP, Tsai HK, Kuo WL, Kung HJ, Wang WC.
    Theranostics; 2021 Jun 01; 11(16):7779-7796. PubMed ID: 34335964
    [Abstract] [Full Text] [Related]

  • 6. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.
    Prostate; 2016 Dec 01; 76(16):1536-1545. PubMed ID: 27473672
    [Abstract] [Full Text] [Related]

  • 7. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM, Hofland J, Teubel WJ, de Ridder CMA, Taylor AE, Graeser R, Arlt W, Jenster GW, van Weerden WM.
    Prostate; 2022 Apr 01; 82(5):505-516. PubMed ID: 35037287
    [Abstract] [Full Text] [Related]

  • 8. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q, Song Z, Ruan H, Wang C, Yang X, Bao L, Wang K, Cheng G, Xu T, Xiao W, Xiong Z, Liu D, Yang M, Zhou D, Yang H, Chen K, Zhang X.
    Clin Cancer Res; 2020 Mar 15; 26(6):1516-1528. PubMed ID: 31796514
    [Abstract] [Full Text] [Related]

  • 9. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
    Dahiya NR, Chandrasekaran B, Kolluru V, Ankem M, Damodaran C, Vadhanam MV.
    Mol Carcinog; 2018 Oct 15; 57(10):1332-1341. PubMed ID: 30069922
    [Abstract] [Full Text] [Related]

  • 10. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.
    Mol Cancer Ther; 2013 Nov 15; 12(11):2342-55. PubMed ID: 23966621
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Shah K, Gagliano T, Garland L, O'Hanlon T, Bortolotti D, Gentili V, Rizzo R, Giamas G, Dean M.
    Oncogene; 2020 Sep 15; 39(39):6172-6189. PubMed ID: 32820253
    [Abstract] [Full Text] [Related]

  • 12. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M, Huang Y, Ratnam M.
    Biochem Biophys Res Commun; 2016 Jul 22; 476(2):69-74. PubMed ID: 27179779
    [Abstract] [Full Text] [Related]

  • 13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec 22; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB, Ji X, Singh SV.
    Mol Cancer Ther; 2018 Oct 22; 17(10):2079-2090. PubMed ID: 30030299
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.